Previous 10 | Next 10 |
ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets. 47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 points. An additional 23% of patients declined less t...
Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid surging interest in a wide swath of meme stocks today, retail investors are once again seeing traction in trading unpopular names. That said, other companies many may not necessarily associate with the meme trade are also ...
Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...
Summary Cassava enters 2023 much as it did 2022 - surrounded by controversy and speculation. 12 months has not been long enough to resolve the fallout from the Citizens Petition filed with the FDA last year by scientists and short sellers of Cassava stock. Cassava is filing a lawsui...
Summary Today, we put Acumen Pharmaceuticals in the spotlight for the first time. The stock of this Alzheimer's focused developmental concern is trading near its net cash on the balance sheet. An investment analysis follows in the paragraphs below. For further ...
Alzheimer’s drug developer Cassava Sciences ( NASDAQ: SAVA ) lost ~13% in the morning hours Thursday to reach the lowest level since mid-September on below-average volume amid concerns over a corporate presentation the company posted for December 2022. About ~1.2M Cassava (...
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. “We mourn profoundly the passi...
Summary Its oral drug candidate for Alzheimer’s disease dementia has an upcoming readout. In other news, Cassava went on the legal counter-offensive against short sellers. Current evidence seems to be more in Cassava’s favor. On Dec. 06, Cassava Sciences ( SAVA...
Cassava Sciences ( NASDAQ: SAVA ) closed up ~10% Wednesday as the biotech indicated it may have open-label study data on its Alzheimer's candidate simufilam ready by the end of the year . The company said it has completed drug administration in the trial of 200 patients with m...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...